Studies of the growth characteristics of myeloma in vitro

by Chan-hyung Park in Toronto

Written in English
Published: Pages: 101 Downloads: 632
Share This

Subjects:

  • Marrow -- Tumors
  • Edition Notes

    Other titlesGrowth characteristics of myeloma in vitro
    ContributionsToronto, University.
    The Physical Object
    Paginationiv, 101 leaves.
    Number of Pages101
    ID Numbers
    Open LibraryOL19531283M

Human hematopoietic cell lines, which had been classified on the basis of studies on clonality, and morphological, chromosomal and functional parameters as lymphoblastoid cell lines (LCL) of presumed non-neoplastic origin, and lymphoma, myeloma and leukemia lines of proven malignant origin, were tested for tumorigenic potential on subcutaneous transplantation to nude mice and for capacity to. Along the uncontrolled myeloma cell growth, MM also causes disruption of the BM and cancer-induced bone disease. Myeloma accounts for ~1–2% of cancers and ~13–15% of all blood cancers and is characterized by clonal proliferation of tumor cells in the BM, monoclonal protein spikes in the blood or urine, and organ shutdown.   Xenograft studies using human MM cell lines treated with miRa and b, and miRa and b antagonists resulted in significant suppression of tumor growth in nude mice. In summary, we have described a MM miRNA signature, which includes miRNAs that modulate the expression of proteins critical to myeloma pathogenesis. Multiple myeloma progression is characterized by a dense interaction between cancer cells and bone marrow microenvironment. The interactions of myeloma cells with various stromal cells and extracellular matrix components are the main regulator of the biological processes that underlie the progression of the disease and of the classic symptomatology correlated.

Determine the impact of this regimen on clonogenic growth of myeloma cells in serial in vitro assays. OUTLINE: This is a pilot study. Patients receive recombinant interferon alfa subcutaneously (SC) once daily. Beginning 1 month later, patients also receive recombinant interleukin-6 SC once daily. In mice, components of both the adaptive (cytolytic killer and helper T lymphocytes) and the innate immune system (natural killer [NK], and NKT cells), as well as IFN-γ are important for the surveillance of spontaneous as well as carcinogen induced tumors (8–10).In human cancer, multiple myeloma provides a valuable opportunity to study these innate and adaptive defense mechanisms, because. Characteristics of patients. For all 31 patients, it was the first episode of IA. in such in vitro studies, these hematopoietic growth factors were added before or simultaneously with steroids to the cells, a fact that does not correspond to how the drugs are used clinically. Neutrophil defect in multiple myeloma: studies . Phases of Cell Growth. It is important to know and record the growth characteristics of the cell line in use before starting any experiments including cell viability and proliferation rates. An alteration in cellular growth can indicate a significant problem within the cell line and if undetected, can have detrimental effects on experimental results.

  Purpose SNS is a highly selective and potent inhibitor of cyclin-dependent kinases (Cdks) 2, 7, and 9, with in vitro growth inhibitory effects and ability to induce apoptosis in malignant B cells. A phase I dose-escalation study of SNS was conducted to evaluate safety, pharmacokinetics, biomarkers of mechanism-based pharmacodynamic (PD) activity, and clinical efficacy. Patients and.   Purpose Four Southwest Oncology Group (SWOG) standard-dose chemotherapy protocols for multiple myeloma (MM) initiated between and were evaluated. The purpose was to clarify the predictive value of specific levels of myeloma-associated monoclonal protein reduction and time to first progression using mature data sets. Patients and Methods Study data on 1, eligible . types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma. Pharmacokinetics Following intravenous administration of mg/m2 and mg/m2 doses to 24 patients with multiple myeloma (n=12, per each dose level), the mean maximum plasma concentrations of.   Introduction. Multiple myeloma (MM) is a hematological malignancy caused by the abnormal expansion of bone marrow-derived plasma cells (Anderson and others ; Kumar and others ; Moreau and others ).MM primarily develops in the bone marrow microenvironment, where the bone marrow stromal cells support the survival and proliferation of MM cells by mediating expression .

Studies of the growth characteristics of myeloma in vitro by Chan-hyung Park Download PDF EPUB FB2

Multiple myeloma (MM) is characterized by unrestrained accumulation of malignant plasma cells (PCs) within the bone marrow (BM), attributed to both loss of apoptotic control and cell-cycle deregulation 1, ts to unravel PC growth through readily available in vitro and in vivo models has raised broad interest, as these allow better understanding of the disease and testing of novel anti Cited by: To develop an in vitro culture system for rapid assessment of multiple myeloma (MM) cell growth.

MM cells lines (MMCLs) L, U, and RPMI, and bone marrow (BM)-derived plasma cells (PCs. Objective. To develop an in vitro culture system for rapid assessment of multiple myeloma (MM) cell growth.

Methods. MM cells lines (MMCLs) L, U, and RPMI, and bone marrow (BM)– derived plasma cells (PCs) from MM patients were evaluated for their in vitro growth using. Figure 3 In vitro growth of plasma cells (PCs) from multiple myeloma (MM) patients. Primary MM cells from 7 of 10 patients could be preserved in culture in the presence of various cytokines, with or without bone marrow stromal cells (BMSCs).Cited by: Cancer Therapy: Preclinical Targeting miR Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth Emanuela Leone1, Eugenio Morelli1, Maria T.

Di Martino1, Nicola Amodio1, Umberto Foresta1, Annamaria Gulla1, Marco Rossi1, Antonino Neri2, Antonio Giordano3,6, Nikhil C. Munshi4,5, Kenneth C. Anderson4, Pierosandro Tagliaferri1, and Pierfrancesco Tassone1,6Cited by: Numerous studies have been devoted to the identification of myeloma cell growth factors (MGF) and to the signalling pathways leading to survival and/or proliferation of myeloma cells.

Disruption of signaling pathways activated by these cytokines may provide a means to affect the growth and induce apoptosis of myeloma plasma cells.

One of the key anti-apoptotic pathways in myeloma is the PI3-kinase/Akt signaling pathway []. In vitro inhibition of this pathway by PI3-kinase and Akt kinase inhibitors induce apoptosis.

Progress in Myeloma: Biology of Myeloma is a collection of research studies dealing with the clinical and experimental plasma cell tumors. This work is composed of 14 chapters that provide a particularly advantageous basis for defining in biochemical and genetic terms the nature of critical alterations in the neoplastic transformation of immunoglobulin producing cells.

A chapter explores the use of anti-idiotypic antibodies in the regulation of the myeloma tumor cell growth and non-neoplastic B cell clones. The concluding chapters look into the chromosomal changes, therapeutic trials, and genetic basis of myeloma. This book will prove useful to oncologists, cell biologists, immunologists, and researchers.

Multiple myeloma, typically characterized by the accumulation of clonal plasma cells in multiple sites of the bone marrow, is the second most common hematologic malignancy with an incidence of 15, patients per year in the United States and a prevalence of approximat Although the majority of patients respond to initial treatment with chemotherapy and radiation, most eventually.

Although these studies demonstrated that mouse myelomas display functional heterogeneity, the growth characteristics of primary human tumors could not be determined until the development of an in vitro culture system by Salmon and Hamburger.

11, 12 In their initial report, more than 86% of tumor samples from patients with multiple myeloma were. Since it has been observed that BMPs modulate growth and survival of myeloma cells in vitro,, we investigated the expression of BMPs, their receptors and intracellular molecules related to BMP signaling in MM BM detect changes in the whole MM BM microenvironment, we compared the expression of BMP2, BMP4, BMP6 and BMP7 in total mononuclear cell population of.

In other studies we demonstrated that heparanase promoted resistance of myeloma cells to anti-myeloma drugs and that by inhibiting heparanase enzyme activity the tumor cells were rendered susceptible to therapy in vitro and in vivo [4,7,8].

Together these discoveries indicate that heparanase may be associated with the emergence of myeloma. MURINE MYELOMA CELLS IN SUSPENSION CULTURE1 O. PETTENGILL and G. SORENSON Department of Pathology, Washington University School of Medicine, Saint Louis, Mo.U.S.A.

Received January 5, THE transplantable murine plasmacytoma X [12] which originated in a C3H mouse is composed of malignant plasma cells (myeloma cells) which synthesize. Multiple myeloma (MM) is an incurable cancer of terminally differentiated plasma cells typically characterized by the abundant production of a monoclonal immunoglobulin.

The purpose of this study is to document the participants characteristics, disease burden, and clinical management of participants in the United States who are treated for relapsed multiple myeloma in routine medical practice with a treatment strategies that include a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as.

Multiple myeloma (MM) describes human plasma cell dyscrasias in which the antibody producing cells, the plasma cell, are malignant. Two of the most common features of the disease include the overproduction of a single type of antibody and bone destruction.

Nilsson K. () Established Cell Lines as Tools in the Study of Human Lymphoma and Myeloma Cell Characteristics. In: Thierfelder S., Rodt H., Thiel E.

(eds) Immunological Diagnosis of Leukemias and Lymphomas. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol Springer, Berlin, Heidelberg.

Macrophages with an M1 "classically activated" profile on the contrary stimulate immune responses in normoxic regions.

The aim of our study was to investigate the characteristics of macrophages in multiple myeloma (MM) looking at phenotype and drug resistance.

We identified TAM on bone marrow sections of MM patients by immunostainings for CD ObjectiveAs an important negative regulatory factor of immunological cells, Tim3 plays a regulating role in tumor immune microenvironment.

The purpose of this study was to investigate the expression of Tim3 on MM cells and its effect on the proliferation and apoptosis of MM cells, as well as its potential sIn this study, the expression of Tim3 was detected on myeloma cells. Abstract. The biology of human multiple myeloma (MM) was poorly understood until recently.

Only when IL-6 had been identified as an important growth factor for MM cells has it been possible to establish cell lines and to maintain fresh MM biopsy cells in vitro for weeks-months (Kawano et alKlein et alNilsson et al ).

This has allowed controlled in vitro studies of various. Trudel S, Ely S, Farooqi Y, et al: Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood, Crossref, Medline, Google Scholar: Paterson JL, Li Z, Wen XY, et al: Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.

study that FLT3 inhibitors (i.e., midostaurin and gilteritinib) exert promising anti-myeloma activity in vitro The most e ff ective induction of apoptosis in primary MM cells was achieved by high.

Criteria for the classification monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group The International Myeloma Working Group Br J. In vitro studies showed that breast cancer cell motility is inhibited by ERα (Platet et al., ). Thus, the reduced ERα levels found in breast cancer cells following their co-culture with the placenta may have supported their migration.

Bone involvement represented by osteolytic bone disease (OBD) or osteopenia is one of the pathognomonic and defining characteristics of multiple myeloma (MM). Nearly 90 % of patients with MM develop osteolytic bone lesions, frequently complicated by skeletal-related events (SRE) such as severe bone pain, pathological fractures, vertebral.

ADVERTISEMENTS: Let us make an in-depth study of the characteristics, differentiation, development, phases and factors affecting plant growth. Characteristics of Plants Growth: Growth is the manifestation of life. All organisms, the simplest as well as the most intricate, are slowly changing the whole time they are alive.

They transform material into more of themselves. From [ ]. A critical role for syndecan-1 in regulating the growth of myeloma tumors has been implied by several previous studies, for example: (i) myeloma growth stimulated via signaling through HGF and epidermal growth factor family ligands is dependent on syndecan-1 heparan sulfate (27, 28); (ii) myeloma cells engineered to overexpress soluble syndecan.

Abstract. Co-culture assays are used to study the mutual interaction between cells in vitro. This chapter describes 2D and 3D co-culture systems used to study cell-cell signaling crosstalk between cancer cells and bone marrow adipocytes, osteoblasts, osteoclasts, and osteocytes.

Introduction. Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells that typically grow in the bone marrow (BM) and produce osteolytic lesions and bone disease in 80% of patients.

1,2 Experimental data 3 and clinical observations 1 suggest that bone disease drives MM progression and that early changes in bone remodeling precede transformation of MM from. CD + /CDwere unable to form colonies in vitro and human engraftment was not detected in any of the mice injected with CD + cells.

A chimeric anti-CD20 monoclonal antibody, rituximab, was showed to inhibit clonogenic growth of CDcells in vitro [6,39].Interestingly, recent studies indicated that restoring or increasing Wnt signaling in myelomatous bones by using DKK1-neutralizing antibody, Wnt3a, or lithium chloride prevented bone disease, stimulated bone formation, and inhibited myeloma growth.

Furthermore, in their in vitro study, Oyajobi et al. demonstrated that bortezomib downregulated.IL induces myeloma cell growth and colony formation via IL receptor and inhibits Th1 immune response. The amount of Th17 cells in the BM positively correlates with clinicopathological characteristics in MM, like clinical tumor stage, serum lactate dehydrogenase concentration, and serum creatinine concentration.